The oncolytic peptide LTX-315, which has been de novo designed based on structure-activity relationship studies of host defense peptides, has the ability to kill human cancer cells and induce specific anticancer immune response when injected locally into tumors established in immunocompetent mice.

2016年4月15日 · LTX-315 is a first-in-class oncolytic peptide-based local immunotherapy that meets these criteria by inducing a type of malignant cell death that elicits anticancer immune responses.

2022年6月14日 · We have recently described the anticancer properties of LTX-315, a novel synthetic anticancer peptide, against syngeneic B16 melanomas. LTX-315 induced a complete regression of B16 melanomas and systemic protective immune responses following intralesional administration of the peptide.

2016年3月10日 · LTX-315 is a cationic amphilytic peptide that preferentially permeabilizes mitochondrial membranes, thereby causing partially BAX/BAK1-regulated, caspase-independent necrosis.

Verrica has in-licensed LTX-315, an oncolytic peptide administered directly to the tumor to induce immunogenic cell death, which may offer a non-surgical option for patients suffering from skin cancer.

LTX-315 is an oncolytic 9-mer peptide of non-viral origin that is in clinical development for the treatment of solid tumors and is currently being evaluated in two separate Phase II clinical trials for skin cancer in the US (NCT04796194) and EU (NCT01986426).

2014年6月25日 · We have recently described the anticancer properties of LTX-315, a novel synthetic anticancer peptide, against syngeneic B16 melanomas. LTX-315 induced a complete regression of B16 melanomas and systemic protective immune responses following intralesional administration of the peptide.

2017年5月11日 · The oncolytic peptide LTX-315, which has been de novo designed based on structure–activity relationship studies of host defense peptides, has the ability to kill human cancer cells and induce specific anticancer immune response when injected locally into tumors established in immunocompetent mice.

2021年8月10日 · We found that breast cancer control by LTX-315 is accompanied by a reconfiguration of the immunological tumor microenvironment that supports the activation of anticancer immunity and can be boosted by radiation therapy.

Lactoferrin-derived lytic peptide LTX-315. NCI Drug Dictionary 2020. A peptide derived from human lactoferrin, with potential lytic and immunostimulating activities. LTX-315 may bind to the tumor cell membranes and subsequently lyse tumor cells, thereby inducing tumor cell necrosis.